163 related articles for article (PubMed ID: 8265981)
21. Clinical application of continuous infusion of recombinant interleukin-2.
West WH
Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S11-5. PubMed ID: 2627985
[TBL] [Abstract][Full Text] [Related]
22. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
[TBL] [Abstract][Full Text] [Related]
23. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
[TBL] [Abstract][Full Text] [Related]
24. Augmentation of natural killer activity, induction of IFN and development tumor immunity during the successful treatment of established murine renal cancer using flavone acetic acid and IL-2.
Hornung RL; Back TC; Zaharko DS; Urba WJ; Longo DL; Wiltrout RH
J Immunol; 1988 Nov; 141(10):3671-9. PubMed ID: 2460546
[TBL] [Abstract][Full Text] [Related]
25. Effects of escalating doses of recombinant human interleukin-2 in correcting functional T-cell defects following autologous bone marrow transplantation for lymphomas and solid tumors.
Bosly A; Guillaume T; Brice P; Humblet Y; Staquet P; Doyen C; Chatelain B; Franks CR; Gisselbrecht C; Symann M
Exp Hematol; 1992 Sep; 20(8):962-8. PubMed ID: 1354620
[TBL] [Abstract][Full Text] [Related]
26. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer.
West WH; Tauer KW; Yannelli JR; Marshall GD; Orr DW; Thurman GB; Oldham RK
N Engl J Med; 1987 Apr; 316(15):898-905. PubMed ID: 3493433
[TBL] [Abstract][Full Text] [Related]
27. Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: a phase II outpatient study.
Atzpodien J; Körfer A; Evers P; Franks CR; Knüver-Hopf J; Lopez-Hänninen E; Fischer M; Mohr H; Dallmann I; Hadam M
Mol Biother; 1990 Mar; 2(1):18-26. PubMed ID: 2334534
[TBL] [Abstract][Full Text] [Related]
28. Three schedules of recombinant human interleukin-2 in the treatment of malignancy: side effects and immunologic effects in relation to serum level.
Sano T; Saijo N; Sasaki Y; Shinkai T; Eguchi K; Tamura T; Sakurai M; Takahashi H; Nakano H; Nakagawa K
Jpn J Cancer Res; 1988 Jan; 79(1):131-43. PubMed ID: 3128501
[TBL] [Abstract][Full Text] [Related]
29. Clonal analysis of peripheral blood lymphocytes from three patients with advanced neuroblastoma receiving recombinant interleukin-2 and interferon alpha.
Prigione I; Facchetti P; Lanino E; Garaventa A; Pistoia V
Cancer Immunol Immunother; 1993 Jul; 37(1):40-6. PubMed ID: 8513451
[TBL] [Abstract][Full Text] [Related]
30. Lysis of human solid tumor cells by lymphokine-activated natural killer cells.
Itoh K; Tilden AB; Balch CM
J Immunol; 1986 May; 136(10):3910-5. PubMed ID: 3084648
[TBL] [Abstract][Full Text] [Related]
31. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
[TBL] [Abstract][Full Text] [Related]
32. Immunological effects of alternative weekly interferon-alpha-2b and low dose interleukin-2 in patients with cancer.
Fiorentino B; Di Stefano P; Giuliani C; Amatetti C; Tinari N; Natoli C; Garufi C; Iacobelli S
Br J Cancer; 1992 Nov; 66(5):981-3. PubMed ID: 1419647
[No Abstract] [Full Text] [Related]
33. Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study.
Negrier S; Philip T; Stoter G; Fossa SD; Janssen S; Iacone A; Cleton FS; Eremin O; Israel L; Jasmin C
Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S21-8. PubMed ID: 2697575
[TBL] [Abstract][Full Text] [Related]
34. Cytotoxic in vitro function in patients with metastatic renal cell carcinoma before and after alpha-2b-interferon therapy. Effects of activation with recombinant interleukin-2.
Feruglio C; Zambello R; Trentin L; Bulian P; Franceschi T; Cetto GL; Semenzato G
Cancer; 1992 May; 69(10):2525-31. PubMed ID: 1568175
[TBL] [Abstract][Full Text] [Related]
35. Phase I study of interleukin-2 and interferon alfa-2a as outpatient therapy for patients with advanced malignancy.
Hirsh M; Lipton A; Harvey H; Givant E; Hopper K; Jones G; Zeffren J; Levitt D
J Clin Oncol; 1990 Oct; 8(10):1657-63. PubMed ID: 2213102
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing.
Meropol NJ; Barresi GM; Fehniger TA; Hitt J; Franklin M; Caligiuri MA
Cancer Immunol Immunother; 1998 Aug; 46(6):318-26. PubMed ID: 9756416
[TBL] [Abstract][Full Text] [Related]
37. A phase I trial of 21-day continuous venous infusion of alpha-interferon at circadian rhythm modulated rate in cancer patients.
Deprés-Brummer P; Levi F; Di Palma M; Beliard A; Lebon P; Marion S; Jasmin C; Misset JL
J Immunother (1991); 1991 Dec; 10(6):440-7. PubMed ID: 1768678
[TBL] [Abstract][Full Text] [Related]
38. Natural killer cells in children with malignant solid tumors. Effect of recombinant interferon-alpha and interleukin-2 on natural killer cell function against tumor cell lines.
Alvarado CS; Findley HW; Chan WC; Hnath RS; Abdel-Mageed A; Pais RC; Kutner MH; Ragab AH
Cancer; 1989 Jan; 63(1):83-9. PubMed ID: 2783377
[TBL] [Abstract][Full Text] [Related]
39. Immunotherapy with intralesional and systemic interleukin-2 of patients with non-small-cell lung cancer.
Scudeletti M; Filaci G; Imro MA; Motta G; Di Gaetano M; Pierri I; Tongiani S; Indiveri F; Puppo F
Cancer Immunol Immunother; 1993 Jul; 37(2):119-24. PubMed ID: 8391391
[TBL] [Abstract][Full Text] [Related]
40. Eradication of mouse melanoma by combined treatment with recombinant human interleukin 2 and recombinant murine interferon-gamma.
Silagi S; Dutkowski R; Schaefer A
Int J Cancer; 1988 Feb; 41(2):315-22. PubMed ID: 3123404
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
